SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

NorthWest Biotherapeutics Inc. (NWBO)

NWBO RSS Feed
Add NWBO Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Barunuuk, Astavakra, sentiment_stocks, Know-Fear, HappyLibrarian
Search This Board: 
Last Post: 12/14/2017 1:00:35 AM - Followers: 546 - Board type: Free - Posts Today: 2







 Stylized Dendritic Cell


"The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of
patients with brain tumors living longer than patients treated at any other hospital.  
Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in
Phase III clinical trials in 46 centers throughout America.  
It is on the road to FDA approval as well as clinical trials throughout Europe.  
Using this vaccine, we are harnessing the patient's immune system, genetics, pathology, brain mapping
and a wide database of bioinformatics to optimize outcomes."

- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA

 


Abstracts
"Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers" - Abstract #2499 - AACR (American Association for Cancer Research)
"Proffered Paper:  Prolonged Survival for Patients with Recurrent Glioblastoma Multiforme who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells" - presented at ITOC-Conference, Munich, Germany - March 26, 2015, 14:40 - Marnix Bosch, Chief Technical Officer, NW Bio (note, abstract linked here is from Science Direct)

NWBO Board of Directors
Cofer Black, Independent Director
Alton L. Boynton, Chief Scientific Officer, Secretary and Director
Robert Farmer, Independent Director
Jerry Jasinowski, Independent Director
Navid Malik, Independent Director
Linda F. Powers, Chairman of the Board, President, CEO and CFO


Corporate Profile

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.

Their lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer.  This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.

Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.  

 They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
 



Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind) 
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz

Company Contact Info
Investor Relations:
Les Goldman  (Company)     (202) 841-7909  lgoldman@nwbio.com
Michael Meehan (Media) (202) 262-9081 mm@SQcomms.com
Jane Searle (Media)  (212) 710-9685  Jane.Searle@mbsvalue.com or media@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)

Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814  (240) 497-9024

DCVAX Survival Stories
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
NWBO GBM Brain Cancer Suvivial Story of Brad Silver
NWBO, GBM Brain Cancer Survival Story of Mike Gregoire
UCLA - Real Stories Using DCVax

Designations & Awards
German Hospital Exemption (referred to as HE) Information for DCVax-L® - FIRST TIME EVER

DCVax-L Hospital Exemption Program Now Under Way in Germany (NWBO, PR Newswire, October 14, 2014)
Two German Approvals:  "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement (NWBO, March 10 2104)
Analysis:  NWBO DCVax-L German Approval Under Hospital Exemption Early Access Program (Smith on Stocks, Nasdaq, March 11, 2014)
Exclusive - Germany OKs Northwest Bio Brain Cancer Drug, Shares Soar (Ransdell Pierson, Reuters, March 10, 2014)

FDA Endpoints & Approval Information
House committee approves bill to speed new drugs to market - May 21, 2015 (Toni Clarke, Reuters)
FDA could approve drugs fro new uses on less data:  draft law - April 29, 2015 (Toni Clarke, Reuters)
Richard Pazdur says FDA racing approvals due to unprecedented efficacy - April 15, 2015 (BioCentury TV)

United Kingdom Awards DC-Vax-L® as Promising Innovative Medicine (PIM) - FIRST TIME EVER
First UK "Promisting Innovative Medicine" Designation Awarded (Department of Health and George Freeman MP, Gov.UK, September 16, 2014)
NWBO's Cancer Vaccine is the First Drug to be Designated by UK Authorities as a "Promising Innovative Medicine" (PIM) - (NWBO, September 16, 2014)


Interviews
Linda Powers Interview 5-15-12

Important or Helpful Links
NWBO Stock Quote & Information
NWBO SEC Filings
NWBO Twitter
NWBO Facebook
NWBO Yahoo Message Board

Upcoming Healthcare Conferences

Institutional Investments
Nearing "the finish line" on cancer vaccine trial, Maryland firm raises $40 million - April 3, 2015 (J.D. Harrison)
Northwest Biotherapeutics:  The $40 Million Woodford Financing is A Major Positive - April 3, 2105 (Smith on Stocks - Larry Smith)


NWBO Analysis
Northwest Biotherapeutics:  FDA Panel Recommendation to Approve Amgen's Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax-Direct - May 1, 2015 (Smith on Stocks - Larry Smith)

Northwest Biotherapeutics:  Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Mulitforme - March 27, 2015 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  How Much Will it Cost to Manufacture DcVax-L - March 5, 2015 (Smith on Stocks - Larry Smith)
The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology - February 3, 2105 (Smith on Stocks - Larry Smith)
Notes from Linda Powers Presentation in San Francisco - January 12, 2015 (Smith on Stocks - Larry Smith)
Current Investment Recommendations for Stocks Covered by SmithOnStocks; A Yearend Review - December 19, 2014 (Smith on Stocks - Larry Smith)
NWBO discussed at great length.
NWBO:  Putting Recent Clinical Data on DCVax Direct in Perspective - November 28, 2014 (Smith on Stocks - Larry Smith)
DCVax-L:  A Reimbursement Perspective - November 22, 2014 (Seeking Alpha - Ryan Pawell)
DCVax-Direct Validation and Updated DCVax-L Ph III Modeling - November 6, 2014 (Seeking Alpha - Steven Giardino [Pyrr])
Now is the Time for Northwest Biotherapeutics - October 29, 2014 (Seeking Alpha - Steven Giardino (Pyrr)
U.K. May Grant Early Patient Access for DCVax-L Priot to Formal Approval  - September 18, 2014 (Seeking Alpha - Larry Smith [Smith on Stocks])
Exciting News on Potential for Early Patient Access for DCVax-L in the UK - September 17, 2014 
(Larry Smith, Smith on Stocks)
The Data Monitoring Commitee Addresses the Status of the DCVax-L Trial - August 13, 2014 (Seeking Alpha - Larry Smith [Smith on Stocks])



NWBO News
NWBO Press Releases 
NWBO Yahoo Headlines

NWBO Older News
NWBO Receives Approval for US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing - Already cleared by FDA for use in Clnical Trials
- December 4, 2009

UK News Coverage
Cancer Treatments - Supplement in United Kingdom Times April 6, 2015
NW Bio Announces $40 Million Financing - Further Equity by Woodford Funds April 2, 2015
Woodford's new biotech could be the next Amgen November 26, 2014 (Gavin Lumsden, Citywire Money)
Neil Woodford invests £16m in brain cancer vaccine company November 19, 2014 (Ashley Armstrong, The Telegraph)

NWBO - Short Seller Rebuttals and Information
Washington Post - Pulitzer Prize Winning Steven Pearlstein addresses NWBO and Short Selling
Citizens for Responsibility and Ethics in Washington (CREW) Requests SEC Investigate Manipulation of Drug Company Stock Price to Benefit Short Sellers
My Dialogue with Adam Feuerstein on Northwest Biotherapeutics - September 25, 2014 (Larry Smith, Smith on Stocks)
Jim Cramer Explains How the Stock Market is Manipulated - sounds a bit like some of the techniques used here.


Patent Information
Espacenet Patent information for NWBO
Patentdocs - Patent applications for NWBO
JUSTIA Patents
NWBO Receives U.S. Patent on Broad Processes for Producing More Potent Dendritic Cells - March 18, 2013 
NWBO's Patent Portfolio is Further Expanded with Manufacturing Automation Patent - September 10, 2013
NWBO Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing - December 4, 2009
NWBO - Wikiinvest Intellectual Property - from the 10-K filed April 15, 2008

Patient Info
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer

Reports
Orphan Drug Report 2014  (EvaluatePharma, October 2014 - see page 14 ) 

Research Posters
AARC April 2015 - Prolonged Survival in Patients with Recurrent Glioblastoma Multiforme Who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells
AARC April 2015 - Clinical and Immunopathological Effects Following Image-guided Intratumoral Injection of Activated, Autologous Dendritic Cells in Patients with Advanced Solid Cancers
SITC 2014 - Direct
ASCO 2014 - Direct

Scientific Advisory Board
Dr. Mac Cheever, Dr. Alfredo Quinoones-Hinojosa, Dr. Jerome Galon, Dr. Samir N. Khleif, Dr. John Smyth
PR Announcement: - June 13, 2016

Sawston Location
US Biotechnology Company Doses Upon Space in Cambridge - link is to i-hub post with story.  Actual story requires sign up.

SEC Reports
Form 10-Q - For fiscal 3rd Quarter ending September 30, 2016
Form 10-Q - for Fiscal 2nd Quarter ending June 30, 2016
Form 10-Q- for Fiscal 1st Quarter ending March 31, 2016
Form 10-K - For fiscal year ended December 31, 2015

Short Report
OTC - FINRA - Equity Short Interest

Stock Quote & Summary
As of October 24, 2017 - approximate and subject to verification 

Common Shares Outstanding:   310,194,613 
Options Outstanding:                    11,343,117
Convertible Notes:                      121,689,276
Share purchase warrants:              TBD

Total Fully Diluted Shares:       443,227,006


Inside Ownership of NWBO Common Stock held (12-01-2016) - DOES NOT include currently exercisable warrants or options - which cannot be voted with: 
 0.2% Security Holders - Employees/Directors                                  399,158  (Boynton, Bosch, Goldman, Farmer, Jasinowski)
0.84% Security Holder - Director                                                    1,285,714  (additionally on 12-27-16 by Jerry Jasinowski)
1.02%  Security Holder  - Linda Powers                                         1,572,500
0.52%    Security Holder - Toucan Capital Fund                                804,145
1.4%    Security Holder- Toucan Partners, LLC                             2,211,784
8.9%  Security Holder – Cognate BioServices (12-1-16)):            13,684,294
16.17%  Security Holder - Woodford Investment Management    24,815,028
2.6%  Security Holder – Dennis Mehiel:                                         4,125,949 (under 5%, not listed on 11-6-15 Proxy)

Total (12-01-2016):                                                                       48,898,572

Total Number of Common Stock Shares:  153,421,687

Highest Share Price after Last Reverse Split:  $12.55 (July 2015)
52-Week High -
 .9799¢
52-Week Low -  .14¢

Transfer Agent:  Computershare Trust Company, N.A.
P.O. Box 30170, College Station, Texas  77842
Monday through Friday. Call (866) 282-9695.

UCLA Department of Neurology
UCLA Interim Chair of Neurosurgery Linda Liau, PhD - Welcome Letter
DCVax in 4th paragraph - "on the road to FDA approval"

A Personal Quest to Cure Brain Cancer - (Into The Brain and Beyond by UCLA Neurosurgery)

UCLA Trials relating to Dendritic Cells
Vaccine Therapy in Treating Patients with Malignant Glioma NCT00612001
Vaccine Therapy in Treating Young Patients Who are Undergoing Surgery for Malignant Glioma NCT00107185
Vaccine Therapy in Treating Patients with Malignant Glioma NCT00068510
Vaccine Therapy in Treating Patients with Stage IV or Relapsed Malignant Melanoma NCT00005617
Autologous Dendritic Cells in Treating Patients with Metastatic Kidney Cancer NCT01826877
Vaccine Therapy in Treating Patients who are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-SMall Cell Lung Cancer NCT00098917
Vaccine for Patients with Newly Diagnosed or Recurrent Low-Grade Glioma NCT01635283
Dendritic Cell Vaccine for Ptients with Brain Tumors NCT01204684
Vaccine Therapy in Treating Patients with Unresected Stage III or Stage IV Melanoma NCT00107159
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients with Locally Advanced or Mestastatic Malignancies NCT02070406

Upcoming Events
ACCR:  Personalized Immunotherapy for glioblastoma - Robert M. Prins, UCLA - Saturday, April 1, 2017, 10:15 to 12:15 p.m. EST - Washington D.C.

Recent  Past Events
Translating Science Into Survival - 2nd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference - Monday, September 25, 5:15 to 7:45 p.m. EST
     Poster presentation (B004) on Direct:  Cytokine production by intratumorally administered activated dendritic cells correlates with survival i a P1 clinical trial in diverse cancers
SMI:  Cancer Vaccines 2016:  Marnix Bosch, MBA, PhD, CTO - DCVax:  Novel personalized immune therapies for solid tumors - Poster  - Wednesday, September 21, 2016
Immunotherapy World - January 25 - 27, 2016
Keynote Presentation by Linda Powers on January 26, 2016 at 9:30 to 9:55 a.m. ET:  DCVax®:  Novel Personalized Immune Therapies for Solid Tumors
SITC's 30th Anniversary Annual Meeting - November 4-8, 2015, National Harbor, MD  At this time, NWBO has a Presentation Booth at this meeting.  Updates will be made as they become available.  "Stay Tuned"
Current SITC Schedule Link

Cancer Vaccines - September 16 to 17, 2015, London, UK.  Linda Powers to speak on "Novel Personalize Immune Therapies for Solid Tumors"

  • Ms. Powers will discuss NW Bio’s DCVax® platform technology, a personalized, dendritic cell based active immunotherapy for solid tumors.
     Unlike conventional cancer drugs and other immune therapies, which use one active agent to hit one target on the cancer, DCVax mobilizes many active agents of the immune system to hit many targets on the cancer.

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:  Translating Science into Survival - September 16, 2015, 6:45 to 8:45 p.m.
A051 Safety, feasibility and activity of intratumoral injection of activated autologous dendritic cells in solid tumors: A phase I clinical trial. Vivek Subbiah, Ravi Murthy, David S Hong, Robert Prins, Chitra Hosing, Robert Brown, Mary McGuire, Aung Naing, Siquing Fu, Quan Lin, Anthony P Conley, Indreshpal Kaur, Marnix L Bosch. 

Videos
Robert Prins, MD - The Future of Vaccine Treatment in Brain Cancer - March 28, 2016, Seattle Science Foundation
    Partial Transcript of Prins' Presentation
Linda Liau, MD - Immunotherapies for GBM:  Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A. - December 15, 2016, Seattle Science Foundation

Webcasts
ASCO 2015 - Overview of DCVax Direct Phase 1 Trial - May 30, 2015 - Webcast by Marnix L. Bosch, MBA, PhD, CTO, NWBO (YouTube)
   Slides presented in ASCO presentation to accompany Video
  Partial Transcription of Dr. Bosch Video
NWBO Virtual Investor Conference - May 7, 2015 - Webcast by Linda Powers, CEO, NWBO (sign-up required)
NWBO Presentation at ITOC2 Conference - March 26, 2015 - Webcast by Marnix L. Bosch, MBA, PhD, CTO, NWBO (YouTube)
NWBO Presentation at BIO CEO & Investor Conference - February 9, 2015 - Webcast by Linda Powers
NWBO Presentation at Phacilitate Immunotherapy World 2015 - January 26, 2015 - Webcast by Linda Powers (YouTube)
Transcript of Biotech Showcase 2015 - from January 12, 2015 - provided by sentiment_stocks
NWBO- 25th Annual Oppenheimer Healthcare Conference - December 10, 2014 - accompanying Slide Show
Transcript of 25th Annual Oppenheimer Healthcare Conference - provided by RK (Includes Q&A at the end)
NWBO Linda Powers Presents at SMi 3rd Cancer Vaccines Conference 2014 - Linda announces England's 1st PIM (Promising Innovative Medicine) Designation and Recent Progress to Date and offers an excellent explanation of how DCVax works

Websites
NWBO Company Website
Wiki page for NWBO
Informative Investor Website
Immunology Acronyms

SureTrader
Interactive Brokers Advertisement
NWBO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NWBO News: Current Report Filing (8-k) 12/07/2017 04:33:36 PM
NWBO News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 12/05/2017 05:25:14 PM
NWBO News: Current Report Filing (8-k) 11/21/2017 06:05:58 AM
NWBO News: Quarterly Report (10-q) 11/20/2017 05:33:26 PM
NWBO News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 11/14/2017 05:20:39 PM
PostSubject
#146747  Sticky Note CALENDAR UPDATE flipper44 12/01/17 12:26:26 PM
#140299  Sticky Note PR About the Lawsuits TC_Trader 10/25/17 09:49:10 AM
#93937  Sticky Note New DCVax Clinical Trial with Opdivo is on clinicaltrials.gov TC_Trader 01/09/17 09:03:10 AM
#44577  Sticky Note Ummm, have any of you people ever read IH Admin [Shelly] 11/08/15 07:37:32 PM
#39690  Sticky Note The topic to be discussed here is NWBO. IH Dan (Retired) 08/31/15 12:21:09 PM
#148280   That certainly is very interesting TiltMyBrain 12/07/17 03:49:47 PM
#148279   If they managed to get blinded interim data VuBru 12/07/17 03:49:00 PM
#148278  Restored Chinatown1980, I don't think you and I are GoodGuyBill 12/07/17 03:46:37 PM
#148277   Volume is unconvincing and not sure if we kabunushi 12/07/17 03:42:38 PM
#148276   Look, if you (pretend you are a company) flipper44 12/07/17 03:40:25 PM
#148275   RegFD is about fair disclosure, and there is kabunushi 12/07/17 03:34:02 PM
#148274   VuBru, SAGE jumped 70% today on release of marzan 12/07/17 03:22:36 PM
#148273   Point taken. I already planned to write to GoodGuyBill 12/07/17 03:18:44 PM
#148272   The web is a very dark place TiltMyBrain 12/07/17 03:18:04 PM
#148271   The Lancet has an eight week holding period TiltMyBrain 12/07/17 03:17:08 PM
#148270   Insider buying is always positive jdheart101 12/07/17 03:14:55 PM
#148269   Fair disclosure. People right now are buying flipper44 12/07/17 03:12:02 PM
#148268   Ah, thanks for the interpretation of your interpretation. antihama 12/07/17 03:09:03 PM
#148267   Where did you get that idea? kabunushi 12/07/17 03:07:26 PM
#148266   No, you are missing the point. Material information flipper44 12/07/17 03:06:03 PM
#148265   Found on the dark net? flipper44 12/07/17 03:01:47 PM
#148264   Tilt - Isn't Friday a common day for VuBru 12/07/17 03:01:45 PM
#148263   Flipper, I think you're making an incorrect assumption. kabunushi 12/07/17 03:00:58 PM
#148262   Ha ha - Exactly! That did the trick. VuBru 12/07/17 02:58:43 PM
#148261   Smokey - I am sure you are correct VuBru 12/07/17 02:58:02 PM
#148260   Exactly. Well put. pgsd 12/07/17 02:46:44 PM
#148259   Or were they given a particular body of writing? TiltMyBrain 12/07/17 02:46:10 PM
#148258   I suspect that the NDA was more around Smokey21 12/07/17 02:42:33 PM
#148257   Holy JC! I think we are on the chinatown1980 12/07/17 02:41:18 PM
#148256   Please communicate your last paragraph directly to the kabunushi 12/07/17 02:15:37 PM
#148255   No, what I'm saying is that if NWBO flipper44 12/07/17 02:14:12 PM
#148254   The word "minimum" does not shield a company flipper44 12/07/17 02:04:44 PM
#148253   So you’re saying antihama 12/07/17 02:03:43 PM
#148252   You did the best explaining the situation that marzan 12/07/17 02:03:22 PM
#148251   Please - those daily Reg SHO figures have XenaLives 12/07/17 02:03:21 PM
#148250   I am not familiar with the Wells case doingmybest 12/07/17 02:02:11 PM
#148249   Non-disclosure agreement VuBru 12/07/17 01:59:10 PM
#148248   No, it isn't too much to ask. Furthermore, GoodGuyBill 12/07/17 01:58:04 PM
#148246   I will be doing basically the same thing doingmybest 12/07/17 01:45:20 PM
#148245   Flipper44, I cannot see a downside to informing doingmybest 12/07/17 01:41:58 PM
#148243   22 tested 3 times. Will it hold? If Sojourner55 12/07/17 01:37:54 PM
#148242   Thanks, Sojo, and if recent history is any Peteydog17 12/07/17 01:37:30 PM
#148240   non disclosure agreement marzan 12/07/17 01:28:44 PM
#148239   50 % to BP ? ! ! ahp123 12/07/17 01:24:43 PM
#148238   Thank you vnda and etrf, I just keep Milner1 12/07/17 01:23:04 PM
#148237   It's better giving than receiving. Hope whatever you Sojourner55 12/07/17 01:03:12 PM
#148235   There was another document posted to the Chardan TC_Trader 12/07/17 12:51:59 PM
#148231   Theoretically, the remaining legal cases should all be flipper44 12/07/17 12:47:54 PM
#148230   Wish I could play the same game but Peteydog17 12/07/17 12:44:06 PM
#148228   I believe one annual meeting is a legal doingmybest 12/07/17 12:41:45 PM
#148226   This is what most people here should do martyDg 12/07/17 12:38:31 PM
#148224   Going down Virgilio 12/07/17 12:26:55 PM
#148222   monentum2 please post the e-mail address for all JTORENCE 12/07/17 12:24:13 PM
#148219   I did that too after watching how fast Sojourner55 12/07/17 12:15:47 PM
#148218   Just will your shares to your kids and Sojourner55 12/07/17 12:14:02 PM
PostSubject